Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients

International Journal of Antimicrobial Agents

Volumn 42, Issue 5, 2013, Pages 384-389

  Adnan, Syamhanin ^a,b,c   Paterson, David L ^b,c   Lipman, Jeffrey ^a,c   Roberts, Jason A ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Ampicillin sulbactam; Critically ill; Multidrug resistant; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM; CEFOPERAZONE; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; IMIPENEM; MEROPENEM; PROBENECID; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG USE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT FAILURE;

AMPICILLIN/SULBACTAM; CRITICALLY ILL; MULTIDRUG-RESISTANT; PHARMACODYNAMICS; PHARMACOKINETICS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMPICILLIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; SULBACTAM;

EID: 84885432565     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.07.012     Document Type: Review

References (75)

1. US Food and Drug Administration. Unasyn (ampicillin/sulbactam): detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) - April 2008.
2. S.P. Hawser, S.K. Bouchillon, C. Lascols, M. Hackel, D.J. Hoban, and R.E. Badal Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009) Clin Microbiol Infect 18 2011 253 259
3. R.I. Waltner-Toews, D.L. Paterson, Z.A. Qureshi, H.E. Sidjabat, J.M. Adams-Haduch, and K.A. Shutt Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended-spectrum-β-lactamase- producing Escherichia coli and the role of TEM-1 hyperproduction Antimicrob Agents Chemother 55 2011 495 501
4. A.S. Levin, C.E. Levy, A.E. Manrique, E.A. Medeiros, and S.F. Costa Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam Int J Antimicrob Agents 21 2003 58 62
5. A.P. Betrosian, F. Frantzeskaki, A. Xanthaki, and G. Georgiadis High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii Scand J Infect Dis 39 2007 38 43
6. B. Spellberg, M. Blaser, R.J. Guidos, H.W. Boucher, J.S. Bradley, and B.I. Eisenstein Combating antimicrobial resistance: policy recommendations to save lives Clin Infect Dis 52 Suppl. 2011 S397 S428
7. M.H. Kollef Optimizing antibiotic therapy in the intensive care unit setting Crit Care 5 2001 189 195
8. P. Espinal, S. Marti, and J. Vila Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces J Hosp Infect 80 2012 56 60
9. A.Y. Peleg, H. Seifert, and D.L. Paterson Acinetobacter baumannii: emergence of a successful pathogen Clin Microbiol Rev 21 2008 538 582
10. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 37 2009 840 851
11. J.A. Roberts Using PK/PD to optimize antibiotic dosing for critically ill patients Curr Pharm Biotechnol 12 2011 2070 2079
12. D.M. Campoli-Richards, and R.N. Brogden Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use Drugs 33 1987 577 609
13. J.D. Williams β-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone Clin Infect Dis 24 1997 494 497
14. M.D. Appleman, H. Belzberg, D.M. Citron, P.N. Heseltine, A.E. Yellin, and J. Murray In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak Antimicrob Agents Chemother 44 2000 1035 1040
15. H.M. Lode Rational antibiotic therapy and the position of ampicillin/sulbactam Int J Antimicrob Agents 32 2008 10 28
16. P.I. Rafailidis, E.N. Ioannidou, and M.E. Falagas Ampicillin/sulbactam: current status in severe bacterial infections Drugs 67 2007 1829 1849
17. American Thoracic Society, and Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
18. M. Hombach, G.V. Bloemberg, and E.C. Bottger Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli J Antimicrob Chemother 67 2012 622 632
19. C.A. Arias, G.A. Contreras, and B.E. Murray Management of multi-drug resistant enterococcal infections Clin Microbiol Infect 2010 2010 23
20. F.D. Wang, M.L. Lin, W.S. Lee, and C.Y. Liu In vitro activities of β-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria Int J Antimicrob Agents 23 2004 590 595
21. J.A. Karlowsky, M.E. Jones, C. Thornsberry, I.R. Friedland, and D.F. Sahm Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001 Antimicrob Agents Chemother 47 2003 1672 1680
22. D.J. Hoban, C. Lascols, L.E. Nicolle, R. Badal, S. Bouchillon, and M. Hackel Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum β-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010 Diagn Microbiol Infect Dis 74 2012 62 67
23. M.N. Al-Hasan, B.D. Lahr, J.E. Eckel-Passow, and L.M. Baddour Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007 J Antimicrob Chemother 64 2009 169 174
24. K.S. Kaye, A.D. Harris, H. Gold, and Y. Carmeli Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients Antimicrob Agents Chemother 44 2000 1004 1009
25. W.D. McMillian, J.L. Bednarik, J.J. Aloi, J.W. Ahern, and B.A. Crookes Utility of ampicillin-sulbactam for empiric treatment of ventilator-associated pneumonia in a trauma population J Trauma 69 2010 861 865
26. K.M. Papp-Wallace, B. Senkfor, J. Gatta, W. Chai, M.A. Taracila, and V. Shanmugasundaram Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3 Antimicrob Agents Chemother 56 2012 5687 5692
27. P.R. Hsueh, R.E. Badal, S.P. Hawser, D.J. Hoban, S.K. Bouchillon, and Y. Ni Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) Int J Antimicrob Agents 36 2010 408 414
28. K.E. Aldridge, C.V. Sanders, and R.L. Marier Variation in the potentiation of β-lactam antibiotic activity by clavulanic acid and sulbactam against multiply antibiotic-resistant bacteria J Antimicrob Chemother 17 1986 463 469
29. J.E. Patterson, P. Farrel, and M.J. Zervos Time-kill kinetic studies of ampicillin/sulbactam for β-lactamase-producing enterococci Diagn Microbiol Infect Dis 14 1991 495 499
30. M. Alexov, P.D. Lister, and C.C. Sanders Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions Antimicrob Agents Chemother 40 1996 2468 2477
31. Y. Hayashi, J.A. Roberts, D.L. Paterson, and J. Lipman Pharmacokinetic evaluation of piperacillin-tazobactam Expert Opin Drug Metab Toxicol 6 2010 1017 1031
32. J.A. Roberts, P. Kruger, D.L. Paterson, and J. Lipman Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36 2008 2433 2440
33. G. Foulds, A.K. Knirsch, J.P. Stankewich, and D.R. Weidler The parenteral kinetics of ampicillin/sulbactam in man Int J Clin Pharmacol Res 5 1985 79 86
34. B. Rohde, U. Werner, H. Hickstein, H. Ehmcke, B. Drewelow, and M. Wenzel Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure Eur J Clin Pharmacol 53 1997 111 115
35. B.R. Meyers, P. Wilkinson, M.H. Mendelson, S. Walsh, C. Bournazos, and S.Z. Hirschman Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers Antimicrob Agents Chemother 35 1991 2098 2101
36. M.C. Nahata, V.I. Vashi, R.N. Swanson, M.A. Messig, and M. Chung Pharmacokinetics of ampicillin and sulbactam in pediatric patients Antimicrob Agents Chemother 43 1999 1225 1229
37. D. Gonzalez, D.J. Conrado, U. Theuretzbacher, and H. Derendorf The effect of critical illness on drug distribution Curr Pharm Biotechnol 12 2011 2030 2036
38. J.A. Roberts, M. Ulldemolins, M.S. Roberts, B. McWhinney, J. Ungerer, and D.L. Paterson Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 2010 332 339
39. G. Foulds, T.J. McBride, A.K. Knirsch, W.J. Rodriguez, and W.N. Khan Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis Antimicrob Agents Chemother 31 1987 1703 1705
40. J.-P. Stahl, J.-P. Bru, G. Fredj, K.W. Brammer, M.-R. Malleret, and M. Micoud Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy Rev Infect Dis 8 Suppl. 1986 S612 S616
41. G. Foulds Pharmacokinetics of sulbactam/ampicillin in humans: a review Rev Infect Dis 8 Suppl. 1986 S503 S511
42. B.N. Kim, A.Y. Peleg, T.P. Lodise, J. Lipman, J. Li, and R. Nation Management of meningitis due to antibiotic-resistant Acinetobacter species Lancet Infect Dis 9 2009 245 255
43. H. Meier, M. Springsklee, and A. Wildfeuer Penetration of ampicillin and sulbactam into human costal cartilage Infection 22 1994 152 155
44. R.A. Blum, R.K. Kohli, N.J. Harrison, and J.J. Schentag Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis Antimicrob Agents Chemother 33 1989 1470 1476
45. F. Pea, and P. Viale The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 42 2006 1764 1771
46. D.R. Park Antimicrobial treatment of ventilator-associated pneumonia Respir Care 50 2005 932 952 discussion 952-5
47. A. Wildfeuer, K.H. Ruhle, P.L. Bolcskei, and M. Springsklee Concentrations of ampicillin and sulbactam in serum and in various compartments of the respiratory tract of patients Infection 22 1994 149 151
48. Y.J. Valcke, M.T. Rosseel, R.A. Pauwels, M.G. Bogaert, and M.E. Van der Straeten Penetration of ampicillin and sulbactam in the lower airways during respiratory infections Antimicrob Agents Chemother 34 1990 958 962
49. M. Wenzel, A. Wildfeuer, and F. Gutsche Pharmacokinetics of ampicillin/sulbactam in patients undergoing colorectal surgery: measurements in serum, the colonic wall and in tissue at the incision site Int J Antimicrob Agents 6 Suppl. 1996 S35 S39
50. Y. Yokoyama, K. Matsumoto, H. Yamamoto, Y. Iguro, Y. Imoto, and K. Ikawa Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery J Infect Chemother 18 2012 878 882
51. S. Jaruratanasirikul, W. Wongpoowarak, N. Aeinlang, and M. Jullangkoon Pharmacodynamics modeling to optimize dosage regimens of sulbactam Antimicrob Agents Chemother 57 2013 3441 3444
52. M. Lindsay Grayson, A. Kucers, S. Crowe, J. McCarthy, J. Mills, and J. Mouton Kucers'. The use of antibiotics 6th ed 2010 Edward Arnold (Publishers) Ltd London, UK
53. R.L. Trotman, J.C. Williamson, D.M. Shoemaker, and W.L. Salzer Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy Clin Infect Dis 41 2005 1159 1166
54. J. Christoff, J. Tolentino, E. Mawdsley, S. Matushek, D. Pitrak, and S.G. Weber Optimizing empirical antimicrobial therapy for infection due to Gram-negative pathogens in the intensive care unit: utility of a combination antibiogram Infect Control Hosp Epidemiol 31 2010 256 261
55. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B.C. McWhinney, and J.P. Ungerer Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 142 2012 30 39
56. C.K. Murray, and D.R. Hospenthal Treatment of multidrug resistant Acinetobacter Curr Opin Infect Dis 18 2005 502 506
57. X. Corbella, J. Ariza, C. Ardanuy, M. Vuelta, F. Tubau, and M. Sora Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii J Antimicrob Chemother 42 1998 793 802
58. C. Urban, E. Go, N. Mariano, B.J. Berger, I. Avraham, and D. Rubin Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus J Infect Dis 167 1993 448 451
59. J.M. Cisneros, M.J. Reyes, J. Pachón, B. Becerril, F.J. Caballero, and J.L. García-Garmendía Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features Clin Infect Dis 22 1996 1026 1032
60. P. Suwangool Use of β-lactam/β-lactamase inhibitor combinations to treat nosocomial pneumonia Infect Dis Clin Pract 11 2002 S27 S33
61. A.P. Betrosian, F. Frantzeskaki, A. Xanthaki, and E.E. Douzinas Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia J Infect 56 2008 432 436
62. G.C. Wood, S.D. Hanes, M.A. Croce, T.C. Fabian, and B.A. Boucher Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia Clin Infect Dis 34 2002 1425 1430
63. L.S. Munoz-Price, and R.A. Weinstein Acinetobacter infection N Engl J Med 358 2008 1271 1281
64. D. Koulenti, and J. Rello Gram-negative bacterial pneumonia: aetiology and management Curr Opin Pulm Med 12 2006 198 204
65. C. Urban, S. Segal-Maurer, and J.J. Rahal Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii Clin Infect Dis 36 2003 1268 1274
66. N. Boyd, and M.D. Nailor Combination antibiotic therapy for empiric and definitive treatment of Gram-negative infections: insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 31 2011 1073 1084
67. P. Pongpech, S. Amornnopparattanakul, S. Panapakdee, S. Fungwithaya, P. Nannha, and C. Dhiraputra Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii J Med Assoc Thai 93 2010 161 171
68. C.H. Lee, Y.F. Tang, L.H. Su, C.C. Chien, and J.W. Liu Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia Microb Drug Resist 14 2008 233 237
69. W. Santimaleeworagun, P. Wongpoowarak, P. Chayakul, S. Pattharachayakul, P. Tansakul, and K.W. Garey In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases Southeast Asian J Trop Med Public Health 42 2011 890 900
70. W.H. Sheng, J.T. Wang, S.Y. Li, Y.C. Lin, A. Cheng, and Y.C. Chen Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU Diagn Microbiol Infect Dis 70 2011 380 386
71. F. Timurkaynak, F. Can, O.K. Azap, M. Demirbilek, H. Arslan, and S.O. Karaman In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units Int J Antimicrob Agents 27 2006 224 228
72. C.R. Kiffer, J.L. Sampaio, S. Sinto, C.P. Oplustil, P.C. Koga, and A.C. Arruda In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii Diagn Microbiol Infect Dis 52 2005 317 322
73. J.Y. Song, S.Y. Kee, I.S. Hwang, Y.B. Seo, H.W. Jeong, and W.J. Kim In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii J Antimicrob Chemother 60 2007 317 322
74. W.C. Ko, H.C. Lee, S.R. Chiang, J.J. Yan, J.J. Wu, and C.L. Lu In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain J Antimicrob Chemother 53 2004 393 395
75. W. Santimaleeworagun, P. Wongpoowarak, P. Chayakul, S. Pattharachayakul, P. Tansakul, and K.W. Garey Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy J Med Assoc Thai 94 2011 863 870